Comments
Loading...

Elevation Oncology

ELEVNASDAQ
Logo brought to you by Benzinga Data
$0.602300
0.00811.36%
Last update: 10:33 AM
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$12.00
Lowest Price Target1
$1.00
Consensus Price Target1
$7.50

Elevation Oncology (NASDAQ:ELEV) Stock, Analyst Ratings, Price Targets, Forecasts

Elevation Oncology Inc has a consensus price target of $7.5 based on the ratings of 10 analysts. The high is $12 issued by HC Wainwright & Co. on December 23, 2021. The low is $1 issued by SVB Leerink on January 9, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., JMP Securities, and JMP Securities on August 7, 2024, July 15, 2024, and June 28, 2024, respectively. With an average price target of $6.67 between HC Wainwright & Co., JMP Securities, and JMP Securities, there's an implied 1006.87% upside for Elevation Oncology Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Apr
3
May
0
0
0
0
Jun
0
0
0
0
Jul
0
0
0
0
Aug
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.9
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
JMP Securities
Piper Sandler
Stephens & Co.
Wedbush

1calculated from analyst ratings

Analyst Ratings for Elevation Oncology

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Elevation Oncology (ELEV) stock?

A

The latest price target for Elevation Oncology (NASDAQ:ELEV) was reported by HC Wainwright & Co. on August 7, 2024. The analyst firm set a price target for $6.00 expecting ELEV to rise to within 12 months (a possible 896.18% upside). 14 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Elevation Oncology (ELEV)?

A

The latest analyst rating for Elevation Oncology (NASDAQ:ELEV) was provided by HC Wainwright & Co., and Elevation Oncology reiterated their buy rating.

Q

When was the last upgrade for Elevation Oncology (ELEV)?

A

The last upgrade for Elevation Oncology Inc happened on May 30, 2023 when SVB Securities raised their price target to $8. SVB Securities previously had a market perform for Elevation Oncology Inc.

Q

When was the last downgrade for Elevation Oncology (ELEV)?

A

The last downgrade for Elevation Oncology Inc happened on November 10, 2022 when JP Morgan changed their price target from N/A to N/A for Elevation Oncology Inc.

Q

When is the next analyst rating going to be posted or updated for Elevation Oncology (ELEV)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Elevation Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Elevation Oncology was filed on August 7, 2024 so you should expect the next rating to be made available sometime around August 7, 2025.

Q

Is the Analyst Rating Elevation Oncology (ELEV) correct?

A

While ratings are subjective and will change, the latest Elevation Oncology (ELEV) rating was a reiterated with a price target of $6.00 to $6.00. The current price Elevation Oncology (ELEV) is trading at is $0.60, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch